Literature DB >> 16887337

HAN11 binds mDia1 and controls GLI1 transcriptional activity.

Kazumasa Morita1, Cristina Lo Celso, Bradley Spencer-Dene, Christos C Zouboulis, Fiona M Watt.   

Abstract

BACKGROUND: The Hedgehog pathway is important in normal and diseased skin. One of the key transcription factors in the pathway is GLI1. GLI1-dependent transcription is positively regulated by DYRK1A, which is reported to bind HAN11. HAN11 is the human homologue of AN11, which controls flavonoid synthesis in plants.
OBJECTIVE: We wanted to identify other binding partners of HAN11 and investigate whether HAN11 regulates GLI1-dependent transcription.
METHODS: We used TAP-tag purification and GST pull down to identify protein-protein interactions and performed luciferase assays of transcriptional activity. We used immunofluorescence microscopy to examine the subcellular distribution of HAN11, mDia1 and GLI1. We performed in situ hybridisation to compare expression of HAN11 with GLI1 and patched in mouse embryos.
RESULTS: We identified the cytoskeletal regulator mDia1 as a binding partner of HAN11. We showed that HAN11 binds the FH2 actin binding domain of mDia1 and confirmed that HAN11 also interacts with DYRK1A. Overexpression of mDia1 or active RhoA caused translocation of HAN11 from nucleus to cytoplasm. HAN11 and mDia1 repressed DYRK1A-dependent GLI1 transcriptional activity. HAN11 overexpression decreased SZ95 sebocyte proliferation and increased cytoplasmic GLI1. AN11 was highly expressed in E10.5 mouse embryo limb buds, in an overlapping pattern with Ptc and GLI1.
CONCLUSION: These results suggest that AN11 may be a physiological regulator of GLI1 transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887337     DOI: 10.1016/j.jdermsci.2006.06.001

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  13 in total

1.  The molecular chaperone TRiC/CCT binds to the Trp-Asp 40 (WD40) repeat protein WDR68 and promotes its folding, protein kinase DYRK1A binding, and nuclear accumulation.

Authors:  Yoshihiko Miyata; Takeshi Shibata; Masato Aoshima; Takuichi Tsubata; Eisuke Nishida
Journal:  J Biol Chem       Date:  2014-10-22       Impact factor: 5.157

2.  Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

Authors:  Samantha D McElyea; John M Starbuck; Danika M Tumbleson-Brink; Emily Harrington; Joshua D Blazek; Ahmed Ghoneima; Katherine Kula; Randall J Roper
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

3.  C. elegans SWAN-1 Binds to EGL-9 and regulates HIF-1-mediated resistance to the bacterial pathogen Pseudomonas aeruginosa PAO1.

Authors:  Zhiyong Shao; Yi Zhang; Qi Ye; Jenifer Neeta Saldanha; Jo Anne Powell-Coffman
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

4.  Dissection of the C-terminal region of E1A redefines the roles of CtBP and other cellular targets in oncogenic transformation.

Authors:  M J Cohen; A F Yousef; P Massimi; G J Fonseca; B Todorovic; P Pelka; A S Turnell; L Banks; J S Mymryk
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

5.  GLI2-specific transcriptional activation of the bone morphogenetic protein/activin antagonist follistatin in human epidermal cells.

Authors:  Thomas Eichberger; Alexandra Kaser; Claudia Pixner; Carmen Schmid; Stefan Klingler; Martina Winklmayr; Cornelia Hauser-Kronberger; Fritz Aberger; Anna-Maria Frischauf
Journal:  J Biol Chem       Date:  2008-03-03       Impact factor: 5.157

6.  The role of mirk kinase in sarcomas.

Authors:  Eileen Friedman
Journal:  Sarcoma       Date:  2011-04-13

7.  Formin' actin in the nucleus.

Authors:  Christian Baarlink; Robert Grosse
Journal:  Nucleus       Date:  2014-02-03       Impact factor: 4.197

Review 8.  Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.

Authors:  Katheleen J Gardiner
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

Review 9.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

10.  The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2.

Authors:  Florian Glenewinkel; Michael J Cohen; Cason R King; Sophie Kaspar; Simone Bamberg-Lemper; Joe S Mymryk; Walter Becker
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.